Core Viewpoint - The company will showcase its pipeline asset CS2015, a dual-specific antibody targeting OX40L and TSLP, at the 2025 ACAAI annual scientific meeting, marking its international debut [1] Group 1: Company Developments - CS2015 is designed with an asymmetric molecular structure that targets two key regulatory factors effective in blocking type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, aiming to extend its in vivo circulation half-life and optimize pharmacokinetic characteristics for prolonged dosing intervals [1] - The stability of CS2015 supports the development of high-concentration subcutaneous formulations, while its excellent developability lays the foundation for high-yield and large-scale production [1] Group 2: Industry Context - The ACAAI is recognized as one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting numerous experts and scholars globally to discuss the latest research findings [1]

Core Viewpoint - Company will showcase its pipeline asset CS2015 at the 2025 ACAAI annual scientific meeting, marking its first appearance at an international academic conference [1] Group 1: Company Developments - CS2015 is a bispecific antibody targeting OX40L and TSLP, which are key regulatory factors that effectively block type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, aiming to extend its in vivo circulation half-life and optimize pharmacokinetic (PK) characteristics for prolonged dosing intervals [1] - CS2015 demonstrates excellent molecular stability, supporting the development of high-concentration subcutaneous formulations [1] Group 2: Industry Context - ACAAI is one of the most influential academic conferences in the field of allergy, asthma, and immunology, attracting experts from around the world to discuss the latest research findings [1] - The complete abstract and electronic poster for CS2015 have been officially published on the ACAAI website [1]

Core Viewpoint - Company will showcase its pipeline asset CS2015 at the upcoming ACAAI annual scientific meeting in 2025, marking its first appearance at an international academic conference [1] Group 1: Company Developments - CS2015 is a bispecific antibody targeting OX40L and TSLP, which are key regulators that effectively block type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, thereby extending its half-life in circulation and optimizing pharmacokinetic (PK) characteristics for prolonged dosing intervals [1] - CS2015 demonstrates excellent molecular stability, supporting the development of high-concentration subcutaneous formulations and ensuring scalability for production [1] Group 2: Industry Context - ACAAI is one of the most influential academic conferences in the field of allergy, asthma, and immunology, attracting experts from around the world to discuss the latest research findings [1] - The complete abstract and electronic poster for CS2015 have been officially published on the ACAAI website, enhancing visibility within the scientific community [1]